Mandeville Therapeutics
Mandeville Therapeutics
About
Mandeville Therapeutics is developing small molecule therapeutics to transform the treatment of chronic kidney disease. Chronic kidney disease affects over 35 million individuals in the US and there is a critical unmet need for new therapeutics. Mandeville’s lead program is designed to improve kidney function with a differentiated approach that targets the endothelin receptor, a clinically validated pathway and has the potential to reduce morbidity and mortality risk.
Get Updates
from LSPA
Stay up-to-date on the latest news and events from Life Sciences PA, insights from the life sciences industry, and so much more!
Life Sciences Pennsylvania was founded in 1989 by a biotech scientist at Penn State University. Today it has grown to represent the entire life sciences industry – biotechnology and diagnostic companies, medical device companies, pharmaceutical companies, investment organizations, research institutions, and myriad service industries that support the life sciences in Pennsylvania.